Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc. (NASDAQ: AMED) is a leading healthcare services company in the United States, specializing in delivering personalized home health, hospice, and high-acuity care services. Headquartered in Baton Rouge, LA, with an executive office in Nashville, TN, the company employs around 18,700 staff across 520 care centers in 37 states and the District of Columbia. Founded in 1982, Amedisys is dedicated to providing quality, clinically-distinctive care to more than 469,000 patients annually, with over 10.6 million visits each year.
Amedisys operates across four key segments: Home Health, Hospice, High Acuity Care, and Personal Care. The Home Health segment offers skilled nursing, therapy, and aid services directly in patients' homes, while the Hospice segment provides end-of-life care to terminally ill patients. The High Acuity Care segment delivers critical inpatient care elements at home, and the Personal Care segment, which was divested in March 2023, offered assistance with daily living activities.
Amedisys's commitment to high-quality care is underpinned by its comprehensive coordination with healthcare providers and personalized care plans tailored to each patient's unique needs. With a strong network involving more than 3,000 hospitals and 110,000 physicians nationwide, Amedisys is a trusted partner in post-acute care.
Recent notable achievements include a merger agreement with UnitedHealth Group, aimed at enhancing patient care through integrated services. Financially, Amedisys reported a net service revenue increase to $571.4 million for Q1 2024, reflecting a robust service demand despite divesting the Personal Care segment.
Additionally, Amedisys is actively involved in advancing healthcare technology. The company has partnered with Patient Choice Laboratories to incorporate advanced molecular testing, enhancing infection diagnosis and patient outcomes. This innovation underscores Amedisys’s commitment to leveraging cutting-edge technology to improve patient care.
For stakeholders, Amedisys remains a prominent figure in the home healthcare industry, constantly adapting and growing to meet the increasing needs of its patient population. The company's strategic partnerships and advancements in healthcare technology position it well for sustained growth and improved patient outcomes.
Amedisys (NASDAQ: AMED) has announced a definitive agreement to acquire regulatory assets for home health care operations in Randolph County, N.C. The acquisition, expected to close on April 30, 2021, allows Amedisys to provide certified home health services to 31,000 Medicare and Medicare Advantage enrollees within a 50-mile radius. Following the acquisition, Amedisys will establish a start-up care center, further enhancing its footprint as the second-largest home health care provider in the U.S., with 320 locations across 34 states.
Amedisys (NASDAQ: AMED) has repurchased approximately $73 million in stock since March 1, 2021, following a $100 million buyback authorization from late 2020. CEO Paul Kusserow stated that this was an advantageous move for shareholders and highlighted the company’s strong cash flow and low leverage, ensuring it won't affect their acquisition strategy. The company remains focused on expanding its home health and hospice services, with a robust pipeline for future growth.
Amedisys, a leading home health and hospice company, announced that CEO Paul B. Kusserow will present at two upcoming conferences: the 42nd Annual Raymond James Institutional Investors Conference on March 3, 2021, at 9:10 a.m. ET, and the Barclays Global Healthcare Conference on March 9, 2021, at 9:45 a.m. ET. Investors can access a live webcast of these presentations via the company’s website. Amedisys serves over 418,000 patients annually and operates 514 care centers across 39 states.
Amedisys has announced the promotions of Christopher Gerard to President and Chief Operating Officer and Scott Ginn to Executive Vice President and Chief Financial Officer, effective immediately. Gerard has led significant growth, expanding Amedisys to 514 care centers across 39 states and achieving an impressive Quality of Patient Care Star score of 4.33. Ginn has been pivotal in growing the company's revenue from $500 million to over $2 billion. Both executives express excitement about leading the company forward while emphasizing quality patient care.
Amedisys reported strong financial results for Q4 2020, with a net service revenue of $550.7 million, up $50 million from 2019. Net income surged to $45.2 million ($1.36 per diluted share) compared to $27.7 million ($0.83) in the prior year. For the full year 2020, net service revenue reached $2.0715 billion, an increase of $115.9 million year-over-year. Amedisys provided optimistic 2021 guidance projecting net service revenue between $2.275 billion to $2.315 billion and adjusted EBITDA of $315 million to $325 million.
Amedisys, Inc. (NASDAQ: AMED) announced it will release its fourth quarter and full-year financial results for 2020 after market close on February 24, 2021. A conference call is scheduled for February 25, 2021 at 11:00 a.m. ET to discuss these results. Interested participants can join via toll-free number (877) 524-8416 or view a live webcast on the company's website. Amedisys provides personalized home healthcare services and partners with over 2,900 hospitals and 78,000 physicians across the U.S.
Amedisys (NASDAQ: AMED) announces a collaboration with Option Care Health (NASDAQ: OPCH) to provide COVID antibody infusion therapy in long-term care facilities. The pilot program, starting in Indianapolis and Valparaiso, Indiana, aims to enhance access to vital therapies for high-risk COVID-19 patients. Amedisys will manage care coordination, while Option Care Health will oversee clinical pharmacy operations and distribute Bamlanivimab. This partnership reflects both companies' commitment to addressing critical healthcare challenges during the pandemic.
Amedisys, a top home health and hospice provider, announced that CEO Paul B. Kusserow will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 p.m. ET. Investors can access the live webcast via the company’s website. Amedisys delivers personalized healthcare at home, serving over 415,000 patients annually through a network of 516 care centers across 39 states and D.C. With a strong focus on patient-centered care, it partners with more than 2,600 hospitals and 67,000 physicians nationwide.
Amedisys, Inc. (NASDAQ: AMED) has authorized a stock repurchase program allowing the company to buy back up to $100 million of its common stock by December 31, 2021. CFO Scott Ginn noted the decision reflects the company's strong cash flow and low leverage, emphasizing that share buybacks will be part of their capital deployment strategy, alongside priority on acquisitions in Home Health and Hospice. Repurchases may occur through various methods, depending on market conditions and legal requirements.
Amedisys has appointed Ivanetta Davis Samuels to its Board of Directors, effective December 15, 2020. Samuels brings over 25 years of legal expertise from her role as Senior Vice President and General Counsel at Meharry Medical College. Amedisys CEO Paul Kusserow emphasizes her experience will enhance the company's leadership as it seeks to provide quality care for aging patients. Samuels expressed her excitement about joining a board predominantly composed of women and supporting equitable healthcare.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What services does Amedisys Inc. provide?
Where is Amedisys Inc. headquartered?
How many employees does Amedisys have?
What is the scope of Amedisys's operations?
How many patients does Amedisys serve annually?
What recent merger has Amedisys entered into?
What recent technological advancement has Amedisys incorporated?
What was Amedisys's net service revenue for Q1 2024?
How does Amedisys coordinate patient care?
What was the Personal Care segment of Amedisys?
